May 052020
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, CA – Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the appointment of Robert Hershberg, M.D., Ph.D. to its board of directors. Dr. Hershberg brings to Fate Therapeutics extensive executive leadership in ...

Fate Therapeutics appoints Dr Rob Hershberg to its Board of Directors

Fate Therapeutics appoints Dr Rob Hershberg to its Board of Directors

From:: Fate Therapeutics appoints Dr Rob Hershberg to its Board of Directors

Sorry, the comment form is closed at this time.